Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Ursodeoxycholic acid (UDCA) treatment has been shown to increase survival without orthotopic liver transplantation (OLT) in patients with primary biliary cirrhosis (PBC) at 4 years. Whether this beneficial effect was maintained over the long term remained to be established. In a large cohort of UDCA–treated patients with PBC, we aimed to determine the 10–year outcome of these patients using two endpoints: (1) survival without OLT, and (2) survival. The cohort was comprised of 225 patients with PBC treated with UDCA (13–15 mg/kg/d) monitored from the beginning of treatment until time of last follow–up, OLT, or death. Because of the absence of a control group, survival without OLT was compared with survival predicted by the Mayo model (first 7 years), and observed 10–year survival with an estimation of survival of a standardized control cohort of the French population. Observed survival without OLT of UDCA–treated patients was significantly higher (P < .04) than survival predicted by the Mayo model. Observed survival was significantly lower (P < .01) than survival predicted from the French population. Observed survival of noncirrhotic patients was not different (P > .9) from that of the French control population but survival of cirrhotic patients was significantly lower (P < .0001). Twenty–two patients died; 13 patients died of hepatic causes and 4 patients died after OLT. In conclusion, survival without OLT among patients treated with UDCA for PBC is higher than that of untreated patients, as predicted by the Mayo model. Ten–year survival among UDCA–treated patients is slightly lower than that of an age– and sex–matched general population, the difference mainly being explained by mortality among cirrhotic patients
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advanced histological stages are consistently associated with a poor prognosis in PBC [93,94,47,63,95].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [94]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Self-citationStaging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Self-citationPoupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487 · cited 5×
“To compare survival of patients under UDCA treatment with survival in the general French population a standardized control cohort was constructed as follows: (1) the actual recorded number of deaths in the French population gave us the average probability of death according to age and gender from 1982 to 1994, (2) for…”
BackgroundMethodInfluentialCOMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Research works printed but not linked: 2
- Combes, 1995, A randomized, double-blind, placebo-controlled trial of ursodeoxycholate in primary biliary cirrhosis, Hepatology, 22, 759
- Poupon, 1997, Bile acids and Immunology, 241
Cited by
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
“In primary biliary cholangitis (PBC) similarly to other chronic liver diseases, advanced histological stages are associated with poor prognosis [180-185]; fibrosis stage was”
BackgroundHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationNew paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
“Placebo-controlled trials showed that UDCA also improves histological features and delays progression to cirrhosis and the time to liver transplantation [9–14].”
BackgroundSelf-citationA comparison of fibrosis progression in chronic liver diseases
Poynard, T., Mathurin, P., Lai, C.-L., Guyader, D., Poupon, R., Tainturier, M.-H., Myers, R. P., Muntenau, M., Ratziu, V., Manns, M., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00413-0 · Cited by 474
Self-citationKuiper, E. M. M., Hansen, B. E., de Vries, R. A., den Ouden–Muller, J. W., van Ditzhuijsen, T. J. M., Haagsma, E. B., Houben, M. H. M. G., Witteman, B. J. M., van Erpecum, K. J., & van Buuren, H. R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.003 · Cited by 460
Corpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Self-citationYerushalmi, B. (2001) · Hepatology · doi:10.1053/jhep.2001.22702 · Cited by 339
“Mitochondrial Immunoblotting for Cytochrome c. Studies were carried out to determine the effect of GCDC, in the presence and absence of antioxidants, upon mitochondrial cytochrome c release in hepatocytes.”
BackgroundInfluentialCorpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Self-citationThe Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Talwalkar, J. A., & Lindor, K. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13808-1 · Cited by 290
Primary biliary cirrhosis: A 2010 update
Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.027 · Cited by 274
“UDCA therapy provides a better survival rate than that predicted by the Mayo model [140–142,168,169].”
MethodSelf-citationPoupon, R. E., Lindor, K. D., Parés, A., Chazouillères, O., Poupon, R., & Heathcote, E. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00192-2 · Cited by 217
Self-citationAl Mamari, S., Djordjevic, J., Halliday, J. S., & Chapman, R. W. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.013 · Cited by 204
“Hence, the improvement in SAP to this level was considered the cornerstone for various well-known definitions of response to UDCA, as in the established Barcelona criteria and Paris criteria [16–18].”
MethodHohenester, S., Oude-Elferink, R. P. J., & Beuers, U. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0164-5 · Cited by 179
Kumagi, T., & Heathcote, E. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-1 · Cited by 174
“UDCA improves 10-year survival [104] and/or delays the progression of hepatic fibrosis in early-stage disease [105], and the development of esophageal varices in patients with PBC [106].”
Corpechot, C., Carrat, F., Poupon, R., & Poupon, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.31880 · Cited by 169
Self-citationAttenuating Endoplasmic Reticulum Stress as a Novel Therapeutic Strategy in Pulmonary Hypertension
Dromparis, P., Paulin, R., Stenson, T. H., Haromy, A., Sutendra, G., & Michelakis, E. D. (2013) · Circulation · doi:10.1161/circulationaha.112.133413 · Cited by 167
Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease
Rockey, D. C. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.011 · Cited by 163
Stanich, P. P., Björnsson, E., Gossard, A. A., Enders, F., Jorgensen, R., & Lindor, K. D. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.12.008 · Cited by 161
ter Borg, P. C. J., Schalm, S. W., Hansen, B. E., & van Buuren, H. R. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00699.x · Cited by 160
Poupon, R. Y., Chazouillères, O., & Poupon, R. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80421-3 · Cited by 169
Self-citationCheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
“3 Untreated, PBC may progress to cirrhosis and liver failure with a median 10-year survival of 50–70%.(4) Treatment with ursodeoxycholic acid (UDCA), at an optimal dose of 13– 15 mg/kg, improves biochemistry and improves transplant-free survival, particularly in early stage PBC.”
BackgroundMyers, R. P., Shaheen, A. A. M., Fong, A., Burak, K. W., Wan, A., Swain, M. G., Hilsden, R. J., Sutherland, L., & Quan, H. (2009) · Hepatology · doi:10.1002/hep.23210 · Cited by 135
Nakamura, M., Shimizu‐Yoshida, Y., Takii, Y., Komori, A., Yokoyama, T., Ueki, T., Daikoku, M., Yano, K., Matsumoto, T., Migita, K., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.016 · Cited by 136
Bezafibrate treatment: a new medical approach for PBC patients?
Kanda, T., Yokosuka, O., Imazeki, F., & Saisho, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-002-1102-7 · Cited by 129
Miki, T., Miura, T., Hotta, H., Tanno, M., Yano, T., Sato, T., Terashima, Y., Takada, A., Ishikawa, S., & Shimamoto, K. (2009) · Diabetes · doi:10.2337/db09-0158 · Cited by 122
Hamczyk, M. R., Villa‐Bellosta, R., Quesada, V., Gonzalo, P., Vidak, S., Nevado, R. M., Andrés‐Manzano, M. J., Misteli, T., López‐Otín, C., & Andrés, V. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809736 · Cited by 119
“…have been approved for clinical use by the U.S. Food and Drug Administration, for example, 4-phenylbutyrate for urea cycle disorders (Maestri et al, 1996; Burlina et al, 2001) and ursodeoxycholic acid for primary biliary cirrhosis (Heathcote et al, 1994; Lindor et al, 1994; Poupon et al, 1999).”
BackgroundHepatotoxicity associated with the ingestion of Centella asiatica
Jorge, O. A., & Jorge, A. D. (2005) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082005000200006 · Cited by 110
Antifibrotic therapy in chronic liver disease
Rockey, D. C. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00445-8 · Cited by 120
Cirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 124
EASL Clinical Practice Guidelines on genetic cholestatic liver diseases
Verkade, H. J., Felzen, A., Keitel, V., Thompson, R. J., Gonzales, E. M., Strnad, P., Kamath, B. M., & van Mil, S. W. C. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.006 · Cited by 121
Henstridge, D. C., Whitham, M., & Febbraio, M. A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.08.003 · Cited by 111
“Chemical chaperones in the clinic From a clinical perspective, PBA has been approved for human use and has been used in trials for multiple diseases [117,118] while TUDCA is the taurine conjugate form of ursodeoxycholic acid (UDCA), used to treat primary biliary cirrhosis [119,120] Given that both PBA and TUDCA have b…”
BackgroundKeitel, V., Dröge, C., & Häussinger, D. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_231 · Cited by 119
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis
Corpechot, C., Chazouillères, O., Belnou, P., Montano-Loza, A. J., Mason, A., Ebadi, M., Eurich, D., Chopra, S., Jacob, D., Schramm, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.043 · Cited by 87
Self-citationUrsodeoxycholic Acid and Long-Term Survival in Primary Biliary Cirrhosis
Levy, C., & Angulo, P. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04094.x · Cited by 99
“and gender-matched unaffected French population (10).”
Use of ursodeoxycholic acid in liver diseases
Kumar, D., & Tandon, R. K. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02376.x · Cited by 99
Kaplan, M. M., Cheng, S., Price, L. L., & Bonis, P. A. L. (2004) · Hepatology · doi:10.1002/hep.20103 · Cited by 87
Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis
Reshetnyak, V. I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7683 · Cited by 86
Jun, I., Izumi, N., Nishimura, Y., Inoue, K., Ueda, K., Nakanishi, H., Tsuchiya, K., Hamano, K., Asahina, Y., Kurosaki, M., et al. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.04.001 · Cited by 85
Gao, X., Fu, L., Xiao, M., Xu, C., Sun, L., Zhang, T., Zheng, F., & Mei, C. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00854.x · Cited by 84
Ursodeoxycholic acid treatment of vanishing bile duct syndromes
Pusl, T. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i22.3487 · Cited by 76
Novel and emerging therapies for cholestatic liver diseases
Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 77
Zhang, T., Baehr, W., & Fu, Y. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9851 · Cited by 63
THE CELL AND MOLECULAR BIOLOGY OF HEPATIC FIBROGENESIS
Rockey, D. C. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70113-6 · Cited by 64
Zhang, Y., Feng, H., Liang, X., He, S., Lan, J., & Li, L. (2022) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2022.01.010 · Cited by 61
Predicting outcome in primary biliary cirrhosis
Lammers, W. J., Kowdley, K. V., & van Buuren, H. R. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30838-5 · Cited by 59
Boone, R. H., Cheung, A. M., Girlan, L. M., & Heathcote, E. J. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-8015-x · Cited by 54
Pharmacological interventions for primary biliary cholangitis
Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 53
Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the pastissues for the future
Poupon, R. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80232-9 · Cited by 56
Self-citationMarine sponge steroids as nuclear receptor ligands
Fiorucci, S., Distrutti, E., Bifulco, G., D’Auria, M. V., & Zampella, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.08.004 · Cited by 55
Obeticholic acid for the treatment of primary biliary cholangitis
Ali, A. H., & Lindor, K. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218471 · Cited by 47
Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats
Oyama, K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.5.885 · Cited by 50
Lammert, C. S., Juran, B. D., Schlicht, E. M., Chan, L. L., Atkinson, E. J., de Andrade, M., & Lazaridis, K. N. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0903-1 · Cited by 50
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 53
Old and new treatments for primary biliary cholangitis
Chascsa, D. M. H., Carey, E. J., & Lindor, K. D. (2017) · Liver International · doi:10.1111/liv.13294 · Cited by 56
Nakano, T., Inoue, K., Hirohara, J., Arita, S., Higuchi, K., Omata, M., & Toda, G. (2002) · Hepatology Research · doi:10.1016/s1386-6346(01)00148-6 · Cited by 50
Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era
Goel, A., & Kim, W. R. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.007 · Cited by 51
Beery, R. M. M., Vaziri, H., & Forouhar, F. (2014) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00024 · Cited by 56
“Treatment with UDCA, particularly for early-stage but also for late-stage PBC, has improved prognostic data compared to decades ago when no medical therapy was available.(32,33) Long-term UDCA has an important long-term therapeutic effect, particularly for patients with nonadvanced, noncirrhotic disease.”
BackgroundDilger, K., Denk, A., Heeg, M. H. J., & Beuers, U. (2005) · Hepatology · doi:10.1002/hep.20568 · Cited by 44
Characteristics of primary biliary cirrhosis in British Columbia's First Nations population
Arbour, L., Rupps, R., Field, L., Ross, P., Erikson, A., Henderson, H., Hill, W., & Yoshida, E. M. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/203028 · Cited by 45
“Treatment with ursodeoxycholic acid (UDCA) has been found to reduce the likelihood of liver transplantation when used in a timely manner (2,3).”
BackgroundResults of long-term ursodiol treatment for patients with primary biliary cirrhosis
Jorgensen, R. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04401-5 · Cited by 45
“These findings are in accordance with a previous study”
ResultHepatic Fibrosis and Cirrhosis
Rockey, D. C. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch105 · Cited by 41
Montaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 44
Gao, R. Y., Shearn, C. T., Orlicky, D. J., Battista, K. D., Alexeev, E. E., Cartwright, I. M., Lanis, J. M., Kostelecky, R. E., Ju, C., Colgan, S. P., et al. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00347-6 · Cited by 37
Methotrexate therapy for primary biliary cirrhosis
Bach, N. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05841-0 · Cited by 41
“Although UDCA does not cure PBC, unlike MTX, UDCA is safe and well tolerated and has a proven benefit on survival”
BackgroundGoh, S., Gull, S. E., & Alexander, G. (2001) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1016/s0306-5456(00)00189-3 · Cited by 38
Medical Treatment of Cholestatic Liver Disease
Paumgartner, G., & Pusl, T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.013 · Cited by 39
A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis
Goet, J. C., Perez, C. F. M., Harms, M. H., Floreani, A., Cazzagon, N., Bruns, T., Prechter, F., Dalekos, G. Ν., Verhelst, X., Gatselis, N., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001285 · Cited by 38
“UDCA-treated patients have reported that the MRS may underestimate survival (8,11,12).”
BackgroundLiu, H. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i11.1652 · Cited by 38
Primary biliary cirrhosis in adults
Momah, N., & Lindor, K. D. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.888950 · Cited by 35
“Initiation of UDCA in individuals with early stages of disease can lead to a normal life expectancy in patients with PBC [20].”
BackgroundPatel, A., & Seetharam, A. B. (2016) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2016.10.001 · Cited by 36
“A subsequent large French cohort study aimed to determine 10-year survival of UDCA-treated patients using endpoints which included transplant-free survival and overall survival.(6) 225 PBC subjects undergoing UDCA (13–15 mg/kg/day) therapy were followed.”
BackgroundMethodBoonstra, K., Bokelaar, R., Stadhouders, P. H. G. M., Tuynman, H. A. R. E., Poen, A. C., van Nieuwkerk, K. M., Witteman, E. M., Hamann, D., Witteman, B. J. M., Beuers, U. H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9530-z · Cited by 36
Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Holtmeier, J., & Leuschner, U. (2001) · Digestion · doi:10.1159/000048854 · Cited by 34
Schönau, J., Wester, A., Schattenberg, J. M., & Hagström, H. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13624 · Cited by 37
Shi, M., Tang, J., Zhang, T., & Han, H. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115164 · Cited by 33
Leung, J., Bonis, P. A. L., & Kaplan, M. M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.05.010 · Cited by 34
Gish, R. G., & Mason, A. L. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70167-7 · Cited by 33
Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges
Trivedi, H. D., Danford, C. J., Goyes, D., & Bonder, A. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s204638 · Cited by 33
Chascsa, D. M. H., & Lindor, K. D. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01664-0 · Cited by 29
Glucocorticosteroids for primary biliary cirrhosis
Prince, M., Christensen, E., & Gluud, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003778.pub2 · Cited by 28
The Role of Lipophilic Bile Acids in the Development of Cirrhotic Cardiomyopathy
Zavecz, J. H., & Battarbee, H. D. (2010) · Cardiovascular Toxicology · doi:10.1007/s12012-010-9069-8 · Cited by 29
“There is suggestive evidence that lipophilic species of bile acids are responsible for some of the hemodynamic disturbances seen in hepatic patients, and chronic administration of a hydrophilic bile acid such as UDCA is sometimes associated with improvement [40].”
BackgroundChanges in the Epidemiology of Primary Biliary Cholangitis
Lleò, A., & Colapietro, F. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.001 · Cited by 28
Primary biliary cirrhosis and bile acids
Corpechot, C. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70016-5 · Cited by 28
Muratori, P., Granito, A., Παππάς, Γ., Muratori, L., Lenzi, M., & Bianchi, F. B. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.09.009 · Cited by 28
Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Rust, C., & Beuers, U. H. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:135 · Cited by 28
Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents
Silveira, M. G., & Lindor, K. D. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.008 · Cited by 27
Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases
Ballot, E., Bandin, O., Chazouillères, O., Johanet, C., & Poupon, R. Y. (2004) · Journal of Autoimmunity · doi:10.1016/j.jaut.2003.11.002 · Cited by 28
Self-citationApoptosis induced by ursodeoxycholic acid in human melanoma cells through the mitochondrial pathway
Yu, H., Fu, Q., Huang, Z., Lin, J., Chen, Q., Wang, Q. L., & Shen, D. (2018) · Oncology Reports · doi:10.3892/or.2018.6828 · Cited by 26
“UDCA is able to improve a series of biochemical and histological parameters (prothrombin time, alkaline phosphatase, alanine transaminase, fatigue, hepatomegaly or splenomegaly) induced by primary biliary cirrhosis, thereby prolonging the patient's survival (29).”
BackgroundEndoplasmic reticulum stress and insulin resistance post‐trauma: similarities to type 2 diabetes
Jeschke, M. G., & Boehning, D. F. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01405.x · Cited by 26
Fatigue in cholestatic liver disease—a perplexing symptom
Kumar, D., & Tandon, R. K. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.921.404 · Cited by 27
Corpechot, C., & Poupon, R. (2007) · Hepatology · doi:10.1002/hep.21871 · Cited by 25
Self-citationGisbert, J. P., Jones, E. A., Pajares, J. M., & Moreno‐Otero, R. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01381.x · Cited by 28
Metadata
- Authors
- Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R.
- Affiliations
- Inserm (FR)
- Corresponding author
- Poupon, Renée Eugénie
- ORCID
- Poupon, Raoul
- Venue
- Hepatology
- Published
- 1999-06
- Volume
- 29
- Issue
- 6
- Pages
- 1668-1671
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2048473231
- Semantic Scholar
- 99291208dd4bc0b499ad3d29ef6c903d615daa5d
- Cited by
- 209
- References
- 19
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 4 · 2018: 8 · 2017: 7 · 2016: 6 · 2015: 8 · 2014: 11 · 2013: 6 · 2012: 11
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 5936 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- PHRC, Assistance Publique-Hôpitaux de Paris (AOM 96045)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, long-term survival, liver transplantation, Mayo risk score, mortality, cirrhotic patients, non-cirrhotic patients, bile acid therapy
- MeSH terms
- Bilirubin, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Prothrombin Time, Serum Albumin, Time Factors, Ursodeoxycholic Acid, Cohort Studies, Survival Analysis, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.